Cao Nan, Zhao Yang, Ma Yanna, Cao Chunxiao, Zhang Haiguo
Nan Cao Department of Oncology, Zunhua People's Hospital, Zunhua, Hengyang, Hebei Province 064200, P.R. China.
Yang Zhao Department of Gastroenterology, Zunhua People's Hospital, Zunhua, Hengyang, Hebei Province 064200, P.R. China.
Pak J Med Sci. 2025 May;41(5):1417-1422. doi: 10.12669/pjms.41.5.11678.
To explore the efficacy and safety of endoscopic submucosal dissection (ESD) in patients with early gastrointestinal (GI) cancer and precancerous lesion.
A total of 132 patients with early GI cancer or precancerous lesion who underwent surgery at Zunhua People's Hospital between March 2021 and June 2023 were retrospectively analyzed. Among them, 65 patients underwent endoscopic mucosal resection (EMR) (Control group), and 67 underwent ESD (ESD group). Perioperative information, treatment outcomes, stress response indicators, miR-146a and miR-199a levels, and incidence of postoperative complications were compared between the two groups.
Surgery duration in the ESD group was significantly longer than that in the Control group. However, the intraoperative blood loss in the ESD group was lower, and the duration of anal ventilation and hospitalization was longer than in the Control group (<0.05). Total treatment efficacy of the ESD group was significantly higher compared to the Control group (<0.05). After the surgery, levels of serum cortisol (Cor), norepinephrine (NE), epinephrine (E), and aldosterone (ALD) in both groups significantly increased compared to those before the surgery, and were significantly lower in the ESD group compared to the Control group (<0.05). After the surgery, expression levels of miR-146a in both groups significantly decreased, while miR-199a levels significantly increased compared to the preoperative levels, and the difference in the ESD group was more significant than in the Control group (<0.05). There was no statistically significant difference in the incidence of complications between the two groups (>0.05).
In patients with early GI cancer or precancerous lesion, ESD can reduce surgical trauma, improve the expression of miR-146a and miR-199a, and alleviate the degree of surgical stress response. ESD is safe and is associated with improved treatment effectiveness and reduce occurrence of complications.
探讨内镜黏膜下剥离术(ESD)治疗早期胃肠道(GI)癌及癌前病变患者的疗效及安全性。
回顾性分析2021年3月至2023年6月在遵化市人民医院接受手术治疗的132例早期GI癌或癌前病变患者。其中,65例患者接受内镜黏膜切除术(EMR)(对照组),67例接受ESD(ESD组)。比较两组患者的围手术期信息、治疗效果、应激反应指标、miR-146a和miR-199a水平以及术后并发症发生率。
ESD组手术时间明显长于对照组。然而,ESD组术中出血量较少,肛门通气时间和住院时间比对照组长(<0.05)。ESD组的总治疗效果明显高于对照组(<0.05)。手术后,两组患者血清皮质醇(Cor)、去甲肾上腺素(NE)、肾上腺素(E)和醛固酮(ALD)水平均较术前显著升高,且ESD组明显低于对照组(<0.05)。手术后,两组miR-146a表达水平均显著降低,而miR-199a水平较术前显著升高,且ESD组差异比对照组更显著(<0.05)。两组并发症发生率差异无统计学意义(>0.05)。
对于早期GI癌或癌前病变患者,ESD可减少手术创伤,改善miR-146a和miR-199a的表达,减轻手术应激反应程度。ESD安全可靠,可提高治疗效果并减少并发症的发生。